Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-240-7133
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.79 million
Profitability
Miscellaneous
Employees30
Next Earnings Date11/21/2019 (Estimated)
OptionableNot Optionable
Heat Biologics (NASDAQ:HTBX) Frequently Asked Questions
What is Heat Biologics' stock symbol?
Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."
When did Heat Biologics' stock split? How did Heat Biologics' stock split work?
Shares of Heat Biologics reverse split on the morning of Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split.
How were Heat Biologics' earnings last quarter?
Heat Biologics Inc (NASDAQ:HTBX) announced its quarterly earnings results on Wednesday, August, 14th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. The biopharmaceutical company had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.91 million. Heat Biologics had a negative net margin of 386.16% and a negative return on equity of 75.51%. View Heat Biologics' Earnings History.
When is Heat Biologics' next earnings date?
What price target have analysts set for HTBX?
3 Wall Street analysts have issued 12 month price targets for Heat Biologics' stock. Their predictions range from $6.00 to $8.00. On average, they anticipate Heat Biologics' stock price to reach $6.67 in the next year. This suggests a possible upside of 1,654.4% from the stock's current price. View Analyst Price Targets for Heat Biologics.
What is the consensus analysts' recommendation for Heat Biologics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heat Biologics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heat Biologics.
Has Heat Biologics been receiving favorable news coverage?
Media coverage about HTBX stock has been trending somewhat negative on Thursday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Heat Biologics earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Heat Biologics.
Are investors shorting Heat Biologics?
Heat Biologics saw a decline in short interest during the month of September. As of September 30th, there was short interest totalling 390,000 shares, a decline of 8.2% from the August 30th total of 424,900 shares. Based on an average daily volume of 197,100 shares, the days-to-cover ratio is currently 2.0 days. Approximately 1.2% of the company's stock are sold short. View Heat Biologics' Current Options Chain.
Who are some of Heat Biologics' key competitors?
Some companies that are related to Heat Biologics include Merrimack Pharmaceuticals (MACK), Oramed Pharmaceuticals (ORMP), Pharmaxis (PXSLY), Catabasis Pharmaceuticals (CATB), Iterum Therapeutics (ITRM), Melinta Therapeutics (MLNT), ASLAN PHARMACEU/ADR (ASLN), OTCMKTS:EMBI (EMBI), VERONA PHARMA P/S (VRNA), Arbutus Biopharma (ABUS), Spring Bank Pharmaceuticals (SBPH), Agile Therapeutics (AGRX), Alpine Immune Sciences (ALPN), SUMMIT THERAPEU/S (SMMT) and Eyenovia (EYEN).
What other stocks do shareholders of Heat Biologics own?
Who are Heat Biologics' key executives?
Heat Biologics' management team includes the folowing people:
- Mr. Jeffrey Alan Wolf, Founder, Chairman, CEO & Pres (Age 56)
- Dr. Jeff T. Hutchins, Chief Scientific Officer & COO (Age 60)
- Mr. Robert J. Jakobs, VP of Fin., Sec. & Controller (Age 64)
- Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory Board
- Colonel George E. Peoples Jr., M.D., FACS, Chief Medical Advisor
How do I buy shares of Heat Biologics?
Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Heat Biologics' stock price today?
One share of HTBX stock can currently be purchased for approximately $0.38.
How big of a company is Heat Biologics?
Heat Biologics has a market capitalization of $12.97 million and generates $5.79 million in revenue each year. The biopharmaceutical company earns $-15,730,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Heat Biologics employs 30 workers across the globe.View Additional Information About Heat Biologics.
What is Heat Biologics' official website?
How can I contact Heat Biologics?
Heat Biologics' mailing address is 801 CAPITOLA DRIVE, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected]
MarketBeat Community Rating for Heat Biologics (NASDAQ HTBX)
MarketBeat's community ratings are surveys of what our community members think about Heat Biologics and other stocks. Vote "Outperform" if you believe HTBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTBX will underperform the S&P 500 over the long term. You may vote once every thirty days.
